semaglutide news oct 26 2025 The NHS will soon offer the weight‑loss medication Wegovy to more than 1 million people with cardiovascular disease to help prevent deadly heart attacks and strokes. Clinical trials show that semaglutide, the ACC 2025: Oral Semaglutide Reduces

This unique approach has shown promising results in both diabetes control and significant weight loss

If adherence challenges persist despite these strategies, healthcare providers may consider alternative treatment options with different dosing frequencies or delivery methods that better align with individual patient needs and preferences

Cardiovascular and Neuroprotective Benefits They also offer potential cardiovascular and neuroprotective benefits, enhancing overall health

Semaglutide GLP-1 can begin to show effects within the first month, though these early results are often subtle

Rapid Kickstart: Experience an initial weight loss of 5-10% in the first 2 months Realistic Goals: A potential total weight loss of 15-20% over six months 5 Life-changing results are finally within reach

With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies